Therapy News and Research

RSS

Positive results from PROLOR Biotech's Factor VIIa-CTP preclinical study on hemophilia

PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.

15 Sep 2011

CHK Nutrition, NeuroResearch Clinics sign consent to halt sale of unapproved amino-acid products

The U.S. Food and Drug Administration announced that two Minnesota companies have agreed to halt distribution of amino-acid products marketed to treat a number of diseases, until requirements of the Federal Food, Drug, and Cosmetic Act are met.

15 Sep 2011

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

ApoPharma Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10 - 2 to recommend that the FDA grant accelerated approval of Ferriprox (deferiprone), an oral iron chelator, for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate.

15 Sep 2011

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

While therapeutic advances have improved survival of patients with follicular lymphoma (FL), it remains an incurable disease with inevitable relapse. This underscores the need for therapies and strategies to extend the duration of remission without significantly increasing toxicity and while maintaining quality of life.

15 Sep 2011

Differences in lifestyle, tumor genetics linked to head and neck cancer in African Americans

Why are African Americans more likely than Caucasians to be not only diagnosed with head and neck cancer, but also die from the disease? While the answer isn't a simple one, differences in lifestyle, access to care and tumor genetics may, in part, be to blame, according to a new study from Henry Ford Hospital.

15 Sep 2011

Consensus panel calls for specialized nutrition therapy to manage obesity

A newly published consensus report prepared by a panel of clinical experts, with sponsorship from Nestle Health Science, reveals that there are opportunities to do more to manage the impact of obesity on the delivery of critical care, particularly in the area of nutrition therapy.

15 Sep 2011

Heart specialists reveal how pacemaker works at the biological level

Heart specialists at Johns Hopkins have figured out how a widely used pacemaker for heart failure, which makes both sides of the heart beat together to pump effectively, works at the biological level.

15 Sep 2011

Fast-track genetic diagnosis for hearing loss

Over 28 million Americans are hearing impaired, and 50 percent of these cases can be traced to genetic causes. The condition can be especially challenging for children born hearing impaired because spoken language, reading, and cognitive development are tied to hearing. That makes early diagnosis essential for identifying appropriate therapy and treatment.

15 Sep 2011

Uterine stem cells could help treat diabetes

Controlling diabetes may someday involve mining stem cells from the lining of the uterus, Yale School of Medicine researchers report in a new study published in the journal Molecular Therapy.

15 Sep 2011

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured.

15 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Glucose metabolism inhibition with 2-DG induces cell death in alveolar rhabdomyosarcoma

A study made by IDIBELL researchers shows that glucose metabolism inhibition with 2-deoxyglucose (2-DG) induces cell death in a type of childhood sarcoma: alveolar rhabdomyosarcoma.

15 Sep 2011

Scientist granted over $138,000 to explore Vitamin C therapy in sepsis

Sepsis kills more people than breast, colorectal, pancreatic, and prostate cancers combined. Outside of coronary care units, it is the leading cause of mortality in intensive care units. Every year 18 million people worldwide develop this potentially fatal disease. Thanks to a generous grant of $138,238.65 from the Jesse and Julie Rasch Foundation, Lawson Health Research Institute's Dr. Michael Sharpe is exploring a new sepsis therapy using Vitamin C.

15 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

New Zealand biotechnology company moves to US

Today leading New Zealand biotechnology company Therapy Cell Ltd announced it was moving to the United States through its merger with Therapy Cells Inc (formerly DIII OTC Market). This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and regeneration of that tissue.

14 Sep 2011

Lucentis receives Health Canada approval to treat vision loss from DME

Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.

14 Sep 2011

NIH awards Rutgers and UMDNJ $23.2M grant to develop drugs against mustard gas

The National Institutes of Health (NIH) has awarded a five-year $23.2 million grant to a group of investigators at Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School to continue their research aimed at developing drug products that could be used against chemical warfare agents from a terrorist attack.

14 Sep 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc., today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant.

14 Sep 2011

USC scientists explore motor memory to foster better rehabilitation for stroke patients

For the first time, scientists at USC have unlocked a mechanism behind the way short- and long-term motor memory work together and compete against one another.

14 Sep 2011

Therapy News and Research

Positive results from PROLOR Biotech's Factor VIIa-CTP preclinical study on hemophilia

CHK Nutrition, NeuroResearch Clinics sign consent to halt sale of unapproved amino-acid products

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

Differences in lifestyle, tumor genetics linked to head and neck cancer in African Americans

Consensus panel calls for specialized nutrition therapy to manage obesity

Heart specialists reveal how pacemaker works at the biological level

Fast-track genetic diagnosis for hearing loss

Uterine stem cells could help treat diabetes

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

Glucose metabolism inhibition with 2-DG induces cell death in alveolar rhabdomyosarcoma

Scientist granted over $138,000 to explore Vitamin C therapy in sepsis

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

New Zealand biotechnology company moves to US

Lucentis receives Health Canada approval to treat vision loss from DME

NIH awards Rutgers and UMDNJ $23.2M grant to develop drugs against mustard gas

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

USC scientists explore motor memory to foster better rehabilitation for stroke patients

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News